Tarsus Pharmaceuticals, Inc. TARS Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price?
- Tarsus Pharmaceuticals, Inc. (TARS) reported share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price of $17.76 in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price increased by 10.0% year-over-year, from $16.15 to $17.76.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price has grown at a 60.3% compound annual growth rate (CAGR), from $1.68 to $17.76.